Dicerna Pharmaceuticals
75 Hayden Avenue
Lexington
Massachusetts
02421
United States
Tel: 617-621-8097
Website: http://www.dicerna.com/
About Dicerna Pharmaceuticals
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. OUR PEOPLE ARE OUR STRENGTH. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.
Stock Exchange: NASDAQ
Stock Symbol: DRNA
At Dicerna, we interfere to silence genes, fight rare diseases, enhance health and advance science. The goal is to leverage our GalXC™ platform and strategic partnerships to get the drug to the patient as quickly as possible. Dicerna is dedicated to our patients and committed to breaking down barriers that slow progress in rare diseases. Dicerna promotes a “no walls” philosophy that fosters a collaborative culture where all employees are valued and respected. Dicerna interferes to help patients and change lives.
325 articles with Dicerna Pharmaceuticals
-
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
12/28/2021
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.
-
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
12/25/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021.
-
Novo Nordisk to Acquire Dicerna
11/18/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna.
-
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
-
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
-
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
11/12/2021
Dicerna Pharmaceuticals, Inc. today announced that Eli Lilly and Company (“Lilly”) has declared proof of principle for the first two targets in the companies’ exclusive relationship in neurodegeneration and pain, under the companies’ global research and licensing collaboration.
-
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
11/12/2021
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® 2021.
-
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
11/9/2021
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
-
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
11/4/2021
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
-
Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021
11/2/2021
Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021.
-
Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
10/19/2021
Dicerna Pharmaceuticals, Inc. today announced top-line results from its PHYOX4 study designed to evaluate the safety and tolerability of a single subcutaneous dose of nedosiran.
-
Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021
10/15/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), today announced an abstract on clinical data from the Company’s PHYOX™2 trial of nedosiran, an investigational GalXC™ RNAi candidate for the treatment of primary hyperoxaluria (PH), has been accepted as a late-breaker poster presentation at the American Society of Nephrology (ASN) Kidney Week 2021 taking place Nov. 4-7, 2021.
-
Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November
10/14/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), today announced that two abstracts related to the Company’s clinical development programs have been accepted for poster presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® taking place Nov. 12-15, 2021.
-
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
10/1/2021
Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 61,350 shares of common stock and 13,650 restricted stock units to be distributed to one new employee with a grant date of Oct. 1, 2021.
-
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
9/28/2021
Dicerna Pharmaceuticals, Inc today announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD, Dicerna’s investigational GalXC™ RNAi therapeutic in development for the treatment of alcohol use disorder (AUD).
-
Dicerna Announces New Executive Leadership Appointments
9/22/2021
Dicerna Pharmaceuticals, Inc. today announced the appointment of Rob Ciappenelli as Chief Strategy Officer
-
Dicerna to Participate in 16th Annual Citi Biopharma Conference
9/2/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 16th Annual Citi Biopharma Conference.
-
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update
8/9/2021
Dicerna Pharmaceuticals, Inc. today reported its financial results for the quarter ended June 30, 2021 and provided a corporate update.
-
Clinical Catch-Up: August 2-6
8/9/2021
It was a busy week for clinical trial announcements. Take a look. -
While the study hit its primary efficacy endpoints, investors are likely concerned about reports of “inconsistent results” regarding reducing Uox excretion in a subtype of patients with the rare disease.